2. Search Result
Search Result
Results for "

bacterial resistance

" in MedChemExpress (MCE) Product Catalog:

52

Inhibitors & Agonists

1

Screening Libraries

2

Biochemical Assay Reagents

9

Peptides

10

Natural
Products

2

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N8393
    Ascr#18

    		Bacterial Fungal Infection
    Ascr#18, an ascaroside, is a hormone of nematodes. Ascr#18 is expressed during nematode development. Ascr#18 increases resistance in Arabidopsis, tomato, potato and barley to viral, bacterial, oomycete, fungal and nematode infections .
    Ascr#18
  • HY-N7378
    N-Hydroxypipecolic acid
    2 Publications Verification

    1-Hydroxy-2-piperidinecarboxylic acid; NHP

    		 Bacterial Inflammation/Immunology
    N-Hydroxypipecolic acid (1-Hydroxy-2-piperidinecarboxylic acid), a plant metabolite and a systemic acquired resistance (SAR) regulator, orchestrates SAR establishment in concert with the immune signal salicylic acid. N-Hydroxypipecolic acid accumulates systemically in the plant foliage in response to pathogen attack. N-Hydroxypipecolic acid induces SAR to bacterial and oomycete infection .
    N-Hydroxypipecolic acid
  • HY-P1674A
    Murepavadin TFA
    2 Publications Verification

    POL7080 TFA

    		 Bacterial Antibiotic Infection
    Murepavadin (POL7080) (TFA), a 14-amino-acid cyclic peptide, is a highly potent, specific antibiotic. Murepavadin exhibits a potent antimicrobial activity for P. aeruginosa with MIC50 and MIC90 values both of 0.12 mg/L. Murepavadin also can target the lipopolysaccharide transport portin D. Murepavadin can be used for the research of bacterial resistance .
    Murepavadin TFA
  • HY-B0013
    Lavofloxacin lactate

    (-)-Ofloxacin lactate

    		 Bacterial DNA/RNA Synthesis Infection
    Lavofloxacin lactate ((-)-ofloxacin lactate) is a class of broad-spectrum antimicrobials that can kill or inhibit a variety of bacteria. Lavofloxacin lactate binds to DNA rotase and topoisomerase IV, resulting in blocked DNA replication and repair, thus inhibiting bacterial growth. Lavofloxacin lactate can be used to study resistance mechanisms in bacteria, including studying resistance genes and mutations .
    Lavofloxacin lactate
  • HY-155504
    Metallo-β-lactamase-IN-11

    		Beta-lactamase Bacterial Infection
    Metallo-β-lactamase-IN-11 (compound 5f) is a Metallo-β-lactamases (MBLs) inhibitor, potent against bacterial metallophyllactamase CphA (IC50=45 µM). Metallo-β-lactamase-IN-11 (10 µM) inhibits NDM-1 by 49% and AIM-1 by 61%. Metallo-β-lactamase-IN-11 can be used in the research of inhibiting antibiotic resistance .
    Metallo-β-lactamase-IN-11
  • HY-P5924
    L-K6L9

    		Bacterial Infection
    L-K6L9 shows antimicrobial and antibiofilm activities against P. aeruginosa from cystic fibrosis patients. L-K6L9 is stable and resistant to degradation by cystic fibrosis sputum proteases and will not induce bacterial resistance .
    L-K6L9
  • HY-P5924A
    D-K6L9

    		Bacterial Infection
    D-K6L9 shows antimicrobial and antibiofilm activities against P. aeruginosa from cystic fibrosis patients. D-K6L9 is stable and resistant to degradation by cystic fibrosis sputum proteases and will not induce bacterial resistance .
    D-K6L9
  • HY-146470
    Antibacterial agent 103

    		Bacterial Infection
    Antibacterial agent 103 (compound 7) has highly antibacterial activity against kinds of Gram-positive and -negative bacteria. Antibacterial agent 103 can be used for researching inhibition of resistance bacterial strains .
    Antibacterial agent 103
  • HY-N7378A
    N-Hydroxypipecolic acid potassium

    1-Hydroxy-2-piperidinecarboxylic acid potassium; NHP potassium

    		 Bacterial Inflammation/Immunology
    N-Hydroxypipecolic acid potassium (1-Hydroxy-2-piperidinecarboxylic acid potassium), a plant metabolite and a systemic acquired resistance (SAR) regulator, orchestrates SAR establishment in concert with the immune signal salicylic acid. N-Hydroxypipecolic acid potassium accumulates systemically in the plant foliage in response to pathogen attack. N-Hydroxypipecolic acid potassium induces SAR to bacterial and oomycete infection .
    N-Hydroxypipecolic acid potassium
  • HY-P1674
    Murepavadin

    POL7080

    		 Bacterial Antibiotic Infection
    Murepavadin (POL7080), a 14-amino-acid cyclic peptide, is a highly potent, specific antibiotic. Murepavadin exhibits a potent antimicrobial activity for P. aeruginosa with both MIC50 and MIC90 values of 0.12 mg/L. Murepavadin also can target the lipopolysaccharide transport portin D. Murepavadin can be used for the research of bacterial resistance .
    Murepavadin
  • HY-158375
    MBL-IN-4

    		Beta-lactamase Bacterial Infection
    MBL-IN-4 (compound 4b) is a MBL inhibitor with the IC50 of 4.81 and 33 μM against IMP-1 and NDM-1 .
    MBL-IN-4
  • HY-155201
    YJ182

    		Bacterial Infection
    YJ182 is a NDM-1 inhibitor (IC50: 0.23 μM). YJ182 also inhibits IMP-1, VIM-2, GIM-1, and MMP-2, with IC50s of 0.25, 0.61, 0.49, and 6.92 μM respectively. YJ182 can be used for bacterial infection research .
    YJ182
  • HY-149809
    AcrB-IN-1

    		Bacterial Infection
    AcrB-IN-1 (Compound H6) is a potent AcrB inhibitor. AcrB-IN-1 can be used for the reversal of bacterial multidrug resistance .
    AcrB-IN-1
  • HY-P10027
    Clovibactin

    		Antibiotic Bacterial Infection
    Clovibactin is an antibiotic for drug-resistant bacterial pathogens without detectable resistance. Clovibactin TFA inihibits cell wall synthesis by targeting pyrophosphate of peptidoglycan precursors .
    Clovibactin
  • HY-155048
    BDM91270

    		Bacterial Infection
    BDM91270 (compound 29) is an E. coli AcrAB-TolC efflux pump inhibitor with an EC90 of 0.6 μM for wild-type E. coli AcrB. BDM91270 can be used in the study of Escherichia coli drug resistance .
    BDM91270
  • HY-161988
    Antimicrobial agent-34

    		Bacterial Infection Inflammation/Immunology
    Antimicrobial agent-34 (compound 4h) is an antibacterial agent (MIC = 1–4 μg/mL), with a clogP value of 9.14. Antimicrobial agent-34 has good plasma stability (HC50 of 131.1 μg/mL) and good membrane selectivity (HC50/MIC is 65.6), with rapid sterilization capability. Antimicrobial agent-34 destroys the integrity of bacterial cell membranes, induces an increase in intracellular reactive oxygen species, and leaks protein and DNA, ultimately leading to bacterial death. Antimicrobial agent-34 demonstrates significant in vivo antibacterial potency in a mouse sepsis model infected with Staphylococcus aureus ATCC43300 .
    Antimicrobial agent-34
  • HY-167841
    Anti-MRSA agent 19

    		Bacterial Antibiotic Infection
    Anti-MRSA agent 19 (Compound 1) is an antibiotic that exhibits activity against S. aureus. Anti-MRSA agent 19 is a active (median MIC=4 μg/mL) against 40 CDC isolates of different bacterial species containing various resistance factors, including vancomycin, aminoglycoside/tetracycline, and oxazolidinone resistance .
    Anti-MRSA agent 19
  • HY-P2036
    FSL-1

    		Toll-like Receptor (TLR) Antibiotic Infection
    FSL-1, a bacterial-derived toll-like receptor 2/6 (TLR2/6) agonist, enhances resistance to experimental HSV-2 infection .
    FSL-1
  • HY-149223
    FtsZ-IN-5

    		Bacterial Infection
    FtsZ-IN-5 is a potent FtsZ inhibitor, to promote FtsZ polymerization and inhibit GTPase activity of FtsZ. Thus, FtsZ-IN-5 inhibits bacterial division to lead to death of bacterial cells. FtsZ-IN-5 shows bactericidal activity with no significant tendency to trigger bacterial resistance as well as rapid bactericidal properties. And FtsZ-IN-5 shows low hemolytic activity and cytotoxicity to mammalian cells .
    FtsZ-IN-5
  • HY-149224
    FtsZ-IN-6

    		Bacterial Infection
    FtsZ-IN-6 is a potent FtsZ inhibitor, to promote FtsZ polymerization and inhibit GTPase activity of FtsZ. Thus, FtsZ-IN-6 inhibits bacterial division to lead to death of bacterial cells. FtsZ-IN-6 shows bactericidal activity with no significant tendency to trigger bacterial resistance as well as rapid bactericidal properties. And FtsZ-IN-6 shows low hemolytic activity and cytotoxicity to mammalian cells .
    FtsZ-IN-6
  • HY-149225
    FtsZ-IN-7

    		Bacterial Infection
    FtsZ-IN-7 is a potent FtsZ inhibitor, to promote FtsZ polymerization and inhibit GTPase activity of FtsZ. Thus, FtsZ-IN-7 inhibits bacterial division to lead to death of bacterial cells. FtsZ-IN-7 shows bactericidal activity with no significant tendency to trigger bacterial resistance as well as rapid bactericidal properties. And FtsZ-IN-7 shows low hemolytic activity and cytotoxicity to mammalian cells .
    FtsZ-IN-7
  • HY-149226
    FtsZ-IN-8

    		Bacterial Infection
    FtsZ-IN-8 is a potent FtsZ inhibitor, to promote FtsZ polymerization and inhibit GTPase activity of FtsZ. Thus, FtsZ-IN-8 inhibits bacterial division to lead to death of bacterial cells. FtsZ-IN-8 shows bactericidal activity with no significant tendency to trigger bacterial resistance as well as rapid bactericidal properties. And FtsZ-IN-8 shows low hemolytic activity and cytotoxicity to mammalian cells .
    FtsZ-IN-8
  • HY-B1599
    Chloramphenicol palmitate

    		Bacterial Antibiotic Infection
    Chloramphenicol palmitate is an orally active broad spectrum antibiotic and has a broad spectrum of activity against gram positive and gram negative bacteria. Chloramphenicol palmitate inhibits bacterial protein synthesis by blocking the peptidyl transferase step. Chloramphenicol palmitate can be used as bacterial selection agent in transformed cells containing chloramphenicol resistance genes .
    Chloramphenicol palmitate
  • HY-153222
    SEQ-9

    		Bacterial Infection
    SEQ-9 is an orally active Mycobacterium tuberculosis (Mtb) 23S bacterial ribosome inhibitor with an IC50 of approximately 170 nM for unmethylated Mtb ribosomes. SEQ-9 also potently inhibits A2296 methylated ribosomes. SEQ-9 can be used to study bacterial infection and drug resistance .
    SEQ-9
  • HY-16752A
    Relebactam sodium

    MK-7655 sodium

    		 Beta-lactamase Bacterial Infection
    Relebactam sodium (MK-7655 sodium) is a potent and selective β-lactamase inhibitor with the activity of delaying the development of bacterial resistance to antibiotics. Relebactam sodium can bind to a variety of β-lactamases, thereby improving the efficacy of β-lactam antibiotics. Relebactam sodium shows good application potential in inhibiting complicated bacterial infections .
    Relebactam sodium
  • HY-N9680
    Coenzyme Q8

    Ubiquinone 8

    		 Endogenous Metabolite Metabolic Disease
    Coenzyme Q8 (Ubiquinone 8) is an isoprenoid quinone that mediates electron transfer within the aerobic respiratory chain and mitigates oxidative stress. Coenzyme Q8 enhances nonspecific resistance to bacterial infections .
    Coenzyme Q8
  • HY-W016477
    Phenazine

    		Bacterial Infection
    Phenazine is an electron shuttles, which modulates the redox state of cells and the downstream gene expression related to biofilm formation and bacterial survival. Phenazines is a biocontrol agents, which affects the growth of plants and induces the systemic resistance in plants .
    Phenazine
  • HY-B1329
    Apramycin sulfate
    3 Publications Verification

    Nebramycin II sulfate

    		 Bacterial Antibiotic Infection
    Apramycin (EBL 1003) is an orally active, acidic pH tolerant and aminoglycoside-modifying-enzymes-tolerant aminoglycoside antibiotic which inhibits protein biosynthesis by targeting the bacterial ribosome. Apramycin is a potential anti-drug-resistance antibiotic .
    Apramycin sulfate
  • HY-162451
    Antibacterial agent 207

    		Bacterial Reactive Oxygen Species Glucosidase Infection
    Antibacterial agent 207 (Compound Ru1) has antibacterial activity against S. aureus (MIC: 1 μg/mL), and low resistance frequencies. Antibacterial agent 207 destroys the bacterial cell membrane, promote production of ROS in bacteria .
    Antibacterial agent 207
  • HY-P10027A
    Clovibactin TFA

    		Antibiotic Bacterial Infection
    Clovibactin TFA is the TFA salt form of Clovibactin (HY-P10027). Clovibactin TFA is an antibiotic for drug-resistant bacterial pathogens without detectable resistance. Clovibactin TFA inihibits cell wall synthesis by targeting pyrophosphate of peptidoglycan precursors .
    Clovibactin TFA
  • HY-130337
    Teicoplanin A2-2

    		Antibiotic Bacterial Infection
    Teicoplanin A2-2 is a glycopeptide antibiotic. Teicoplanin A2-2 exhibits antibacterial activity, particularly against coagulase-negative staphylococci (CNS). Teicoplanin A2-2 inhibits bacterial cell wall synthesis by competitively binding to the terminal D-Ala-D-Ala peptide bonds in the cell wall synthesis process, leading to bacterial death. Teicoplanin A2-2 can be used for research into bacterial resistance mechanisms and the development of new antibiotics .
    Teicoplanin A2-2
  • HY-B1599R
    Chloramphenicol palmitate (Standard)

    		Bacterial Antibiotic Infection
    Chloramphenicol palmitate (Standard) is the analytical standard of Chloramphenicol palmitate. This product is intended for research and analytical applications. Chloramphenicol palmitate is an orally active broad spectrum antibiotic and has a broad spectrum of activity against gram positive and gram negative bacteria. Chloramphenicol palmitate inhibits bacterial protein synthesis by blocking the peptidyl transferase step. Chloramphenicol palmitate can be used as bacterial selection agent in transformed cells containing chloramphenicol resistance genes .
    Chloramphenicol palmitate (Standard)
  • HY-W001132
    Indole
    1 Publications Verification

    		 Endogenous Metabolite Infection
    Indole is an aromatic, heterocyclic, organic compound which widely distributed in the natural environment and can be produced by a variety of bacteria. Indole regulates various aspects of bacterial physiology, including spore formation, plasmid stability, resistance to drugs, biofilm formation, and virulence as an intercellular signal molecule .
    Indole
  • HY-W107077
    INF55

    		Others Infection
    INF55 is a NoA multidrug resistance pump inhibitor with the activity of inhibiting the NoA pump. The heterocomplex formed by INF55 combined with berberine shows the potential to combat the resistance of bacterial compounds. INF55 can enhance the antibacterial activity of berberine by reducing its efflux. The structural variants of INF55 can show different NoA inhibitory activities, thereby affecting the antibacterial effect of its corresponding heterocomplexes. Different derivatives of INF55 show similar activity in terms of antibacterial dose and effectiveness .
    INF55
  • HY-149013
    Anti-MRSA agent 5

    		Bacterial Infection
    Anti-MRSA agent 5 (B14) is a potent
    MRSA
    agent with MIC50 values of 0.38 μg/mL and has low hERG activity with an IC50 values of >40 μM. Anti-MRSA agent 5 (B14) also has low cytotoxicity to mammal cells and unlikely to acquire bacterial resistance .
    Anti-MRSA agent 5
  • HY-N6869
    Dehydroabietic acid

    		Antibiotic PPAR Bacterial Fungal Infection Metabolic Disease Inflammation/Immunology Cancer
    Dehydroabietic acid is a diterpene resin acid that can be isolated from Pinus and Picea. Dehydroabietic acid has anti-bacterial, anti-fungal, anti-inflammatory, and anticancer activities. Dehydroabietic acid is a dual PPAR-α/γ agonist and PPAR-γ partial agonist, which can attenuate insulin resistance (IR) and hepatic steatosis induced by HFD-consumption in mice .
    Dehydroabietic acid
  • HY-162818
    Antibacterial agent 237

    		Bacterial Reactive Oxygen Species Infection
    Antibacterial agent 237 (compound Ru-8) is a bacteriostatic agent for Staphylococcus aureus, with MIC of 0.78-1.56 μg/mL. Antibacterial agent 237 destroys bacterial cell membranes, changes their permeability, and induces bacteria to produce Reactive Oxygen Species, leading to bacterial death without causing drug resistance. Antibacterial agent 237 has low hemolytic toxicity to rabbit red blood cells and Raw 264.7 cells, and has significant antibacterial effects against Staphylococcus aureus in mouse skin wound infection models and Bacillus major larvae infection models .
    Antibacterial agent 237
  • HY-B0887
    Permethrin
    1 Publications Verification

    NRDC-143

    		 Parasite Mitochondrial Metabolism Sodium Channel Na+/K+ ATPase Infection Neurological Disease
    Permethrin (NRDC-143) is an insecticide, acaricide and a high selectively inhibitor of the Mitochondrial complex I, found in sediment and water samples. Permethrin shows estrogenic in vivo and anti-estrogenic activity in vitro. Permethrin also acts as a neurotoxin affecting neuron membranes by prolonging Sodium channel activation. Permethrin decreases resistance to bacterial infections in medaka (Oryzias latipes) .
    Permethrin
  • HY-P2036A
    FSL-1 TFA
    3 Publications Verification

    		 Toll-like Receptor (TLR) MMP HSV Antibiotic Infection
    FSL-1 TFA, a bacterial-derived toll-like receptor 2/6 (TLR2/6) agonist, enhances resistance to experimental HSV-2 infection . FSL-1 TFA induces MMP-9 production through TLR2 and NF-κB/AP-1 signaling pathways in monocytic THP-1 cells .
    FSL-1 TFA
  • HY-149734
    MA220607

    		Bacterial Infection
    MA220607 is an antibacterial agent with low hemolytic toxicity and a dual-target mechanism of action (MOA). MA220607 promotes FtsZ protein polymerization, also increases the permeability of bacterial membranes and inhibits biofilm formation. The resistance rate of MA220607 is low, and the MICs against Gram-positive bacteria and Gram-negative bacteria are Table 0.062-2 μg/mL and 0.5-4 μg/mL, respectively) .
    MA220607
  • HY-N6869R
    Dehydroabietic acid (Standard)

    		Antibiotic PPAR Bacterial Fungal Infection Metabolic Disease Inflammation/Immunology Cancer
    Dehydroabietic acid (Standard) is the analytical standard of Dehydroabietic acid. This product is intended for research and analytical applications. Dehydroabietic acid is a diterpene resin acid that can be isolated from Pinus and Picea. Dehydroabietic acid has anti-bacterial, anti-fungal, anti-inflammatory, and anticancer activities. Dehydroabietic acid is a dual PPAR-α/γ agonist and PPAR-γ partial agonist, which can attenuate insulin resistance (IR) and hepatic steatosis induced by HFD-consumption in mice .
    Dehydroabietic acid (Standard)
  • HY-P3078
    Amphomycin

    		Bacterial Antibiotic Infection
    Amphomycin is a lipopeptide antibiotic that inhibits peptidoglycan synthesis and blocks cell wall development. Amphomycin exhibits potent antibacterial activities against methicillin-resistant S. aureus (MRSA), vancomycin-resistant enterococci (VRE), penicillin-gentamicin-erythromycin-resistant S. pneumonia, and linezolid-quinupristin-dalfopristin-resistant enterococci .
    Amphomycin
  • HY-153335
    Enpp-1-IN-16

    		Phosphodiesterase (PDE) Infection Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
    Enpp-1-IN-16 (compound 54) is an ENPP1 inhibitor. Enpp-1-IN-16 has the potential to study cancer, especially in cases of high ENPP1 expression or elevated cytoplasmic DNA levels. Enpp-1-IN-16 can also be used in other diseases mediated by ENPP1, such as bacterial or viral infections, insulin resistance and type II diabetes, chondrocalcinosis and osteoarthritis, calcium pyrophosphate deposition disorder (CPPD), low Phosphatase disease and soft tissue calcification disorders .
    Enpp-1-IN-16
  • HY-147546
    Antibacterial agent 107

    		Bacterial Infection
    Antibacterial agent 107 (compound 14) is a potent antibacterial agent. Antibacterial agent 107 shows potent antibacterial activity against Gram-positive bacteria, with a MIC of 1.56 μg/mL (MRSA). Antibacterial agent 107 exhibits low hemolytic activity, high membrane selectivity, and rapid bactericidal activity. Antibacterial agent 107 shows effective in vivo efficacy in the murine model of bacterial keratitis caused by Staphylococcus aureus ATCC29213 .
    Antibacterial agent 107
  • HY-B1455
    Clindamycin
    5+ Cited Publications

    		 Bacterial Antibiotic Parasite Infection Cancer
    Clindamycin is an orally active and broad-spectrum bacteriostatic lincosamide antibiotic. Clindamycin can inhibit bacterial protein synthesis, possessing the ability to suppress the expression of virulence factors in Staphylococcus aureus at sub-inhibitory concentrations (sub-MICs). Clindamycin resistance results from enzymatic methylation of the antibiotic binding site in the 50S ribosomal subunit (23S rRNA). Clindamycin decreases the production of Panton-Valentine leucocidin (PVL), toxic-shock-staphylococcal toxin (TSST-1) or alpha-haemolysin (Hla). Clindamycin also can be used for researching malaria .
    Clindamycin
  • HY-B1455S
    Clindamycin-d3 hydrochloride

    		Bacterial Antibiotic Parasite Infection
    Clindamycin-d3 (hydrochloride) is the deuterium labeled Clindamycin. Clindamycin is an orally active and broad-spectrum bacteriostatic lincosamide antibiotic. Clindamycin can inhibit bacterial protein synthesis, possessing the ability to suppress the expression of virulence factors in Staphylococcus aureus at sub-inhibitory concentrations (sub-MICs). Clindamycin resistance results from enzymatic methylation of the antibiotic binding site in the 50S ribosomal subunit (23S rRNA). Clindamycin decreases the production of Panton-Valentine leucocidin (PVL), toxic-shock-staphylococcal toxin (TSST-1) or alpha-haemolysin (Hla). Clindamycin also can be used for researching malaria[1][2].
    Clindamycin-d3 hydrochloride
  • HY-B1455R
    Clindamycin (Standard)

    		Bacterial Antibiotic Parasite Infection Cancer
    Clindamycin (Standard) is the analytical standard of Clindamycin. This product is intended for research and analytical applications. Clindamycin is an orally active and broad-spectrum bacteriostatic lincosamide antibiotic. Clindamycin can inhibit bacterial protein synthesis, possessing the ability to suppress the expression of virulence factors in Staphylococcus aureus at sub-inhibitory concentrations (sub-MICs). Clindamycin resistance results from enzymatic methylation of the antibiotic binding site in the 50S ribosomal subunit (23S rRNA). Clindamycin decreases the production of Panton-Valentine leucocidin (PVL), toxic-shock-staphylococcal toxin (TSST-1) or alpha-haemolysin (Hla). Clindamycin also can be used for researching malaria .
    Clindamycin (Standard)
  • HY-N4314
    Scutellarein tetramethyl ether
    1 Publications Verification

    4',5,6,7-Tetramethoxyflavone

    		 Bacterial COX NO Synthase NF-κB Infection Inflammation/Immunology Cancer
    Scutellarein tetramethyl ether (4',5,6,7-Tetramethoxyflavone) is a bioactive compound extracted from Eupatorium odoratum. Scutellarein tetramethyl ether exhibits anti-inflammatory, antibacterial, pro-coagulant, and anti-tumor activities. Scutellarein tetramethyl ether exerts its anti-inflammatory effects by modulating the NF-κB pathway and regulates bacterial resistance through the inhibition of efflux pumps. Additionally, Scutellarein tetramethyl ether accelerates coagulation time via the endogenous coagulation pathway. Studies have shown that Scutellarein tetramethyl ether can effectively inhibit the growth of the liver cancer cell line HepG2 (IC50= 20.08 μg/mL) .
    Scutellarein tetramethyl ether
  • HY-B1455S1
    Clindamycin-13C,d3

    		Isotope-Labeled Compounds Bacterial Antibiotic Parasite Infection
    Clindamycin- 13C,d3 is the 13C- and deuterium labeled Clindamycin. Clindamycin is an orally active and broad-spectrum bacteriostatic lincosamide antibiotic. Clindamycin can inhibit bacterial protein synthesis, possessing the ability to suppress the expression of virulence factors in Staphylococcus aureus at sub-inhibitory concentrations (sub-MICs). Clindamycin resistance results from enzymatic methylation of the antibiotic binding site in the 50S ribosomal subunit (23S rRNA). Clindamycin decreases the production of Panton-Valentine leucocidin (PVL), toxic-shock-staphylococcal toxin (TSST-1) or alpha-haemolysin (Hla). Clindamycin also can be used for researching malaria[1][2][3].
    Clindamycin-13C,d3
  • HY-12826
    IMB-XH1

    		Beta-lactamase Bcl-2 Family Bacterial Cancer
    IMB-XH1 is an inhibitor of myeloid cell factor 1 (Mcl-1) . IMB-XH1 is a non-competitive Delhi metallo-β-lactamase (NDM-1) inhibitor. The IC50s of IMB-XH1 against metallo-β-lactamases NDM-1, IMP-4, ImiS and L1 are 0.4637 μM, 3.980 μM, 0.2287 μM and 1.158 μM, respectively .
    IMB-XH1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: